Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ready prime time
6 mil eaten ....yummy
here comes the short covering....
here is what is available to be borrowed - dropped from 10mil really fast.
Recent Data
Fee Available Updated
1.1 % 150,000 2021-02-10 14:30:03
1.1 % 2,200,000 2021-02-10 14:15:03
1.1 % 2,400,000 2021-02-10 14:00:03
1.1 % 3,400,000 2021-02-10 13:45:03
1.1 % 5,500,000 2021-02-10 13:30:03
1.1 % 5,600,000 2021-02-10 13:15:02
1.1 % 5,900,000 2021-02-10 13:00:03
1.1 % 7,300,000 2021-02-10 12:45:03
1.1 % 8,300,000 2021-02-10 12:30:03
1.1 % 8,300,000 2021-02-10 12:15:02
1.1 % 8,300,000 2021-02-10 12:00:03
1.1 % 10,000,000 2021-02-10 11:45:03
1.1 % 10,000,000 2021-02-10 11:30:03
1.1 % 10,000,000 2021-02-10 11:15:03
1.1 % 10,000,000 2021-02-10 11:00:02
1.1 % 10,000,000 2021-02-10 10:45:03
1.1 % 10,000,000 2021-02-10 10:30:03
1.1 % 10,000,000 2021-02-10 10:15:04
1.1 % 10,000,000 2021-02-10 10:00:03
40 mil on the bid @ 0.0006 cdel
something brewing?
hiding on the bid / ask started yesterday afternoon.....
looking good for bottom fishing
More in-depth tumor analysis presents new therapeutic options for patients with advanced cancer - From McGill University 2019
News
The Segal Cancer Centre is the only Canadian site to participate in an international effort to match patients with personalized medications by delving deeper into tumor biology, offering better options for treating advanced cancer
Published: 29Apr2019
An international clinical trial, published in Nature Medicine, revealed that combining RNA and DNA profiling gives a far more precise indication of the active biological elements within a tumor, enabling clinicians to more accurately determine which targeted therapies could improve survival among patients with advanced cancer. This marks the first clinical trial in cancer to add gene expression on top of DNA aberration. The Segal Cancer Centre at the Jewish General Hospital (JGH) was the only Canadian site in this pioneering effort undertaken by the Worldwide Innovative Networking in Personalized Cancer Medicine (WIN Consortium), of which the Segal Cancer Centre is a founding member.
“The premise behind the WINTHER study was to consider therapy options based on the observed characteristics of an individual’s tumor, rather than aggregating based on larger group studies,” said Dr. Wilson Miller, Director of the Clinical Trials Unit at the Segal Cancer Centre and one of the principal investigators on the research. Dr. Miller is a Professor of Medicine at McGill University. “We have determined that analysis of the genetic mutations in a tumor doesn’t necessarily isolate the active elements that represent the best clinical targets. This trial showed that profiling RNA gives us a more accurate picture of the molecules that drive tumor progression in an individual case and, where we can target those molecules, we achieve much better results. Because DNA and RNA are not directly aligned in cancer cells, this added dimension of profiling is very important to personalizing treatment.”
The 107 patents who received treatment in the study had late stage disease for which there was little hope of improvement. All had already received extensive treatments, with one-quarter having received at least five prior lines of therapy. Nonetheless, more than 26% of the participants experienced at least six months of partial or complete response to the new therapies introduced as a result of the combination RNA and DNA profiling. More than 22% experienced survival that surpassed the previously expected norm.
One of the JGH patients had colorectal cancer in which the gene HER2/NEU, which is more often associated with breast cancer, was expressed. This patient was given a drug that acts on that mutation and the patient had a very positive response. Without identifying the presence of this gene, it is unlikely that anyone would have thought to treat a colorectal cancer patient with a drug generally used for breast cancer.
WINTHER involved centres in five countries. The lead researchers held weekly clinical management conferences, which were invaluable in their ability to collaborate. Health Canada was instrumental in allowing the application of experimental treatments in connection with this trial.
“Typically, results from a study on advanced cancer patients can help us introduce personalized treatments early in the progression of the disease,” explained Dr. Gerald Batist, Director of the Segal Cancer Centre and a Professor of Oncology at McGill University. “We anticipate that precision treatment that can elicit a response in the most advanced cases will have even more dramatic benefit when they are applied before the disease has had a chance to progress. The sooner we can introduce what prove to be the most effective medications, the stronger their impact is likely to be.”
The next phase WINTHER trial will recruit patients earlier in their cancer trajectory in order to further demonstrate the positive effects of precision medicine in cancer. An even deeper level of analysis is to identify the actual proteins underlying the gene expression, and researchers at the Lady Davis Institute at the JGH are actively pursuing this path of inquiry.
https://www.mcgill.ca/newsroom/channels/news/more-depth-tumor-analysis-presents-new-therapeutic-options-patients-advanced-cancer-296530
Sunshine Biopharma Looking to Mimic Roche’s Billion-Dollar Cancer Drug
(from 2011)
Last year, over 260,000 new cases of breast cancer (invasive and in situ combined) were diagnosed in women in the US. Over the course of a woman’s lifetime, the odds are greater than 12% (or 1 out of every 8) that she will develop invasive breast cancer and have only about a 41% chance of surviving for 5 years if not detected until stage IIIB (odds are increased to approximately 90% if caught in stage I). Although most people don’t consider it, men aren’t removed from invasive breast cancer stats either; nearly 2,000 new cases were diagnosed in 2010 as well.
Given the high death rate for late-stage detection (odds slip all the way to a meager 15% chance of living 5 more years when detected in stage 4), there is a huge area of unmet need for new therapies to treat the disease. One company looking to make a dent in the number of breast cancer deaths is Montreal, Canada-based Sunshine Biopharma, Inc., a drug maker engaged in researching and developing drugs for a wide array of cancers with their initial focus on breast cancer.
Sunshine is taking the path less traveled by attacking drug-resistant cancers, a course of action that can be difficult, but reap impressive rewards if successful and Sunshine is showing promising results to date. The company’s flagship compound in development is Adva-27, a small molecule that targets and inhibits Topoisomerase II (Top2), an enzyme found in abundance in various types of aggressive carcinomas. It is widely known that there are two genes associated with aggressive forms of cancer: Her2 (human epidermal growth factor receptor-2) and Top2. Swiss drug maker Roche’s Herceptin (Trastuzumab) is an effective treatment for Her2-positive patients. Showcasing the magnitude of usage for a viable indication addressing one of the genes, Herceptin generated roughly $7 billion in global sales for Roche in 2010.
Recently, Sunshine announced it has completed a detailed cytotoxicity study, a measure of a drug’s ability to destroy cancer cells in vitro, of Adva-27a, in MCF-7/MDR, a multidrug-resistant breast cancer cell line. According to the company, the study’s results showed that Adva-27a is 16-times more effective at killing multidrug-resistant breast cancer cells than Etoposide, a current commonly used drug. In addition, data generated by the study revealed that Adva-27a is unaffected by the molecular machinery that are responsible for making cancer cells resistant to drugs. Multidrug resistance is a major component in the failure of many of today’s chemotherapies, so drugs that show the ability to thwart the resistance factor are heralded as particularly valuable from both a humanitarian and financial standpoint.
Hiding deep withing the 900 page proposed merger agreement :
The Business Milestones are as follows:
-receipt of purchase orders for 500 AYRO vehicles from Club Car in calendar year 2020, consisting of 30 vehicles in the first fiscal quarter of 2020,60 vehicles in the second fiscal quarter of 2020, 150 vehicles in the third fiscal quarter of 2020, and 260 vehicles in the fourth fiscal quarter of 2020,with a minimum gross margin of 19%;
-reaching an agreement in 2020 with Club Car or Ingersoll Rand, resulting in at least a $1.5 million equity investment in the combined company,which investment shall be publicly disclosed, by May 31, 2020;
Merger tomorrow ; then in the next 2 days an equity stake by Ingersoll Rand (who as part of the distribution agreement can purchase up to 51% of Ayro)
GLTA
From the 10k : Since October 1999, Danone SA, through subsidiaries (collectively “Danone”), has been the beneficial owner of approximately 22% of the outstanding common stock of Lifeway.
Rolling into the april futures tonight - would expect that the baseline will be lower.
Did not hold overnight
My pleasure
SVXY - it is 1x short vix - rather than 2x vix(TVIX)
Ready for blue sky breakout !!!
Okay - details please
thx
Regarding the factory
To my understanding ;
there was a date set for the agreement & ground breaking ceremony
That did not happen
I understood the terms of the agreement were still being sorted
Radio silence since
Yes, there are elements that I believe are real.
Rather my approach has changed due to exogenous events.
Corona virus is going to have a big economic impact - see the fed 50 point emergency cut yesterday. That is extraordinary and does not bode well for the short and medium term outlook.
It all depends on ones perspective - like TNO long term and willing to accept a huge price drop (his words - "don't care if it goes to .02 cents").
I always believed the brain-trust was in Korea - which is currently enduring a public health crisis.
Doing my DD - I definitely questioned Tammy Billington CFO (as per OTCmarkets). I did find her on Honeybook though.
https://www.honeybook.com/profile/tammy-d-billington/saean-motors-ev-bakersfield-ca
Wishing all green trades
Peace
Wishing you all good luck
Peace
I don't think that is good news.
Either is the fact that there is no confirmed Factory in Korea.
The news out of South Korea could be a headwind for SAEAN as all of the R&D is there.
South Korea stocks drop more than 3% as country raises coronavirus alert to ‘highest level’
Published Sun, Feb 23 20206:37 PM EST
Early days for South Korea - hoping to avoid a public health crisis.
Corona virus might be an existential threat here
FYI
The number of people being tested for coronavirus in South Korea has risen to 2,707, up from 1,860 last night.
12500 @ .20 on the ask
or $2500 buy and this is back at .24
sounds about right
And now that weak hands have been shook ... are we going to walk back up and close above .24 ?
52 Week High today !!!!
Just getting started here and completely under the radar - Still has lots of room to the upside
Common sense ain’t too common any more.
My dad used to say - If common sense was so common - more people would have it....
Here is my take on the situation ;
Saean loaned EMPM a little more than $1 million dollars.
That money will be converted back into EMPM shares.
Do your DD and check the T&Cs on those loans.
Problem solved - no more sweating this issue.
FTman
Looking really good here :)
.30 anyone
My pleasure.
Registration link to Ely webinar on Thursday (should be interesting to say the least): https://register.gotowebinar.com/register/7099413944312858881?source=MC
Get ready for some news tomorrow morning - thinking it is going to be really good.
Yes - it halted @ 12:44pm ; post the press release you referenced.
Still expecting a buy-out from another royalty co.